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Covalent conjugation of Toll-like receptor ligands (TLR-L) to
synthetic antigenic peptides strongly improves antigen presen-
tation in vitro and T lymphocyte priming in vivo. These molec-
ularly well defined TLR-L-peptide conjugates, constitute an
attractive vaccinationmodality, sharing the peptide antigen and
a defined adjuvant in one singlemolecule.We have analyzed the
intracellular trafficking andprocessing of twoTLR-L conjugates
in dendritic cells (DCs). Long synthetic peptides containing an
ovalbumin cytotoxic T-cell epitope were chemically conjugated
to two different TLR-Ls the TLR2 ligand, Pam3CysSK4 (Pam) or
the TLR9 ligand CpG. Rapid and enhanced uptake of both types
of TLR-L-conjugated peptide occurred in DCs. Moreover,
TLR-L conjugation greatly enhanced antigen presentation, a proc-
ess that was dependent on endosomal acidification, proteasomal
cleavage, and TAP translocation. The uptake of the CpG conju-
gatewas independent of endosomally-expressedTLR9 as reported
previously. Unexpectedly, we found that Pamconjugated pep-
tideswere likewise internalized independently of the expression
of cell surface-expressed TLR2. Further characterization of the
uptake mechanisms revealed that TLR2-L employed a different
uptake route than TLR9-L. Inhibition of clathrin- or caveolin-
dependent endocytosis greatly reduced uptake and antigen
presentation of the Pam-conjugate. In contrast, internalization
and antigen presentation of CpGconjugates was independent
of clathrin-coated pits but partly dependent on caveolae forma-
tion. Importantly, in contrast to theTLR-independent uptake of
the conjugates, TLR expression and downstream TLR signaling
was required for dendritic cell maturation and for priming of
naı¨ve CD8 T-cells. Together, our data show that targeting to
two distinct TLRs requires distinct uptake mechanism but fol-
lows similar trafficking and intracellular processing pathways
leading to optimal antigen presentation and T-cell priming.
Toll-like receptors (TLR)3 are germ line-encoded receptors
expressedmainly on cells of the innate immune system, such as
granulocytes, macrophages, and dendritic cells (DCs). These
receptors are important in sensing infectious agents through
recognition of pathogen-associatedmolecules and act as a com-
municator between innate and adaptive immune responses.
The receptors are expressed either on the cell surface or in the
endosomal organelles. This compartmentalization of the TLR
correlates with the type of ligandswithwhich they interact. The
TLRs expressed on the cell surface bind to extracellular com-
ponents of the microorganisms (such as bacterial LPS to TLR4,
bacterial lipopeptide to TLR2). In contrast, the TLRs found in
the endosomes bind to ligands derived from intracellular mol-
ecules of the pathogen, such as unmethylated CpG DNA
sequences toTLR9 and single-strandedRNA toTLR7 (1). Stud-
ies have shown that ligands interacting with the latter type of
TLRs are internalized independently of the TLRs (2). Upon
engagement of the ligand to its receptor, a cascade of intracel-
lular signaling events is initiated that involves docking of differ-
ent adaptor molecules such as MyD88 and TRAM to the TLR
receptors and recruitment of proteins belonging to the IRAK-
family, which ultimately culminate in the activation of the
NF transcription factor and gene transcription leading to
production of proinflammatory cytokines (3).
DCs are both initiators and regulators of T cell responses (4).
Dendritic cells constantly screen the environment for potential
foreign antigens by a variety of mechanisms such as phagocy-
tosis, macropinocytosis, caveolin-mediated, or clathrin-
dependent endocytosis. Themanner of uptake is dependent on
the size and nature of material to be internalized (5, 6). As
specialized antigen-presenting cells, DCs have the capacity to
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efficiently process exogenous proteins and present the peptides
in major histocompatibility complex (MHC) class I molecules,
a process known as cross-presentation. In this scenario exog-
enously derived antigens are internalized and translocate from
the endosomal route into the cytosol, where the proteasome
complex processes the antigen. The generated peptides are
transported from the cytosol into the endoplasmic reticulum
via the peptide transporter TAP (7), after which the peptides
undergo further trimming and are finally loaded onto MHC
class I molecules, which translocate to the cell surface, where
the peptide is presented to CD8 T-cells.
The ability of DCs to cross-present peptides on MHC class I
to CD8 T-cells together with the capacity of TLR ligands to
deliver maturation signals has inspired efforts to explore the
use of DCs as a vaccine vehicle in the fight against infectious
diseases and cancer (8, 9). Covalent linkage of immunogenic
peptides to the TLR9 ligand, CpG DNA, or TLR2 ligands, like
Pam3CysSS andPam3CysSK4, induces amore prominentT-cell
response than administration of free TLR2-L or TLR9-Lmixed
with protein (2, 10–16).
To explore the mode of action of TLR-L antigen conjugates,
we have designed well defined synthetic vaccines composed of
peptides containing the model antigen ovalbumin CD8 cyto-
toxic T-lymphocyte (CTL) epitope (SIINFEKL) chemically
linked to either the TLR2-ligand, Pam3CysSK4, or the TLR9
ligand, CpG. These conjugates were used to study the uptake,
intracellular routing, and processing. We show that not only
TLR9-L conjugates but also the TLR2-L conjugates are taken
up independently of TLR expression albeit through two distinct
internalization mechanisms. Down-stream processing route
for MHC class I antigen presentation, however, were similar
and requires endosomal acidification, TAP translocation, and
proteasomal processing. Importantly, whereas the uptake of
both types of TLR-L conjugates was independent of TLR
expression, priming of specific CD8 T-cell response required
TLR signaling in dendritic cells.
EXPERIMENTAL PROCEDURES
Mouse Strains and Chemicals
C57BL/6 (B6; H-2b) were obtained from Charles River Lab-
oratories. TLR2-deficient mice were purchased from Jackson
Laboratories, whereas the TLR9-deficient mice were obtained
from S. Akira Osaka University, Osaka, Japan. Bone marrow
fromTAP-deficientmice andTAP/2-microglobulin-deficient
mice strains was kindly provided by Prof. H. G. Ljunggren,
Karolinska Institutet, Sweden. LPS of Escherichia coli (sero-
type026:B6), Monodansylcadaverine (MDC), and filipin were
purchased from Sigma-Aldrich. Epoxomicin and chlorophenol
red--D-galactopyranoside were from Calbiochem.
Cell Lines
Freshly isolated DCs were cultured from mouse bone mar-
row cells as described elsewhere (17). D1 cell line, a long term
growth factor-dependent immature splenic DC line derived
from B6 (H-2b) mice, was cultured as described (18). B3Z is a
T-cell hybridoma specific for the H-2Kb CTL epitope SIIN-
FEKL that expresses a -galactosidase construct under the reg-
ulation of the NF-AT element from the IL2 promoter (19). EG7
(EL4-OVA) (20) was cultured in completemediumwith 400g
of G418 (Invitrogen).
Generation of Pam3CysSK4- or CpG-conjugated Peptides and
Labeling
Table 1 shows the conjugates and peptides used in this study.
Chemicals
HCTUwas purchased from IRIS Biotech GmbH (Germany),
and Pam3Cys-OHwas from Bachem. PyBOP (benzotriazole-1-
yl-oxytrispyrrolidinophosphonium hexafluorophosphate) was
purchased from MultiSynTech GmbH. Reactive fluorescent
dyes BODIPY-FL N-(2-aminoethyl) maleimide, Alexa Fluor
488 C5 maleimide, and Alexa Fluor 488 carboxylic acid succin-
imidyl ester were purchased from Invitrogen. Fmoc amino
acids were from SENN Chemicals or from MultiSynTech
GmbH. Tentagel-based resins were purchased at Rapp Poly-
mere GmbH. All chemicals and solvents used in the solid phase
peptide synthesis were from Biosolve. Chemicals, resins, and
solvents used in the solid phaseDNAsynthesis except Beaucage
reagent and Control Pore Glass support used to introduce
3-thiol modification were from Proligo and were used as
received. 3-Thiol modifier C3 S-S Control Pore Glass and
Beaucage reagent were purchased at Glen Research. All chem-
icals were used as received.
General Methods
Mass spectra were recorded on a PE SCIEX API 165
(PerkinElmer Life Sciences) mass spectrometer. Analytical liq-
uid chromatography/mass spectroscopy was conducted on a
Jasco system using an Alltima C18 analytical column (4.6 150
mm, 5-m particle size, flow 1.0 ml/min) with detection at 214
and 254 nm. The solvent system was 100% water (A), 100%
acetonitrile (B), and 1% trifluoroacetic acid (C). Gradients of A
to B were applied over 15min, keeping C isocratic at 10%. Puri-
fications of the synthetic peptides were conducted on a
BioCAD Vision automated HPLC system (PerSeptive Biosys-
tems, Inc.) supplied with a Alltima C18 column (10 250 mm,
5-m particle size, running at 4 ml/min). A Varian DMS 200
UV-visible spectrophotometer was used to measure UV
absorption MALDI-time-of-flight spectra were recorded on a
Voyager-DE PRO mass spectrometer (Perseptive Biosystems,
Inc.).
Peptide Synthesis
Fmoc-based solid-phase peptide synthesis was performed on
a CS Bio 336 automated instrument (CS Bio Co.) starting from
either preloaded Fmoc-Leu-PHB-Tentagel resin or from
Tentagel -RAM resin. The synthesis was performed on a 50- or
250-mol scale according to established methods (21). HCTU
was used as coupling reagent. All peptides (see Table 1) were
cleaved from the resin using trifluoroacetic acid/triisopropylsi-
lane/H2O (95/2.5/2.5) for 2 h at room temperature, precipitated
from diethyl ether, redissolved in 20% aqueous 1,1,1,3,3,3-
hexafluoro-2-propanol, and purified by reverse phase HPLC
and characterized using liquid chromatography/mass spectros-
copy and MALDI mass spectroscopy (see “General Methods”).
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Oligonucleotide Synthesis
DMT-based solid-phase phosphorothioate oligonucleotide
(ODN) synthesis was performed on an Expedite automated
instrument (Perseptive Biosystems) starting fromControl Pore
Glass support with the 3-thiol modifier. The syntheses were
performed on a 10-mol scale according to established meth-
ods (22). Elongation was performed using 3-phosphoramidite
derivatives of DMT-protected nucleosides 5-DMT-A(TAC)-
OH, 5-DMT-C(TAC)-OH, 5-DMT-G(TAC)-OH, and
5-DMT-T-OH under the agency of dicyanoimidazole. After
each coupling, remaining free 5-hydroxyls were blocked using
a capping solution (t-butylphenoxyacetic anhydride (Tac2O)/
1-methylimidazole in tetrahydrofuran/pyridine) followed by
sulfurization of the phosphite linkage to the phosphorothioate
linkage using the Beaucage reagent. Next, the 5-DMT protecting
group was removed by trichloroacetic acid, after which elonga-
tion was continued. After final DMT removal the DNA oli-
gomer was cleaved from the resin by 25% ammonium hydrox-
ide solution to give a 3-disulfide modified ODN (ODN-SS-
propyl-OH). ODNs were purified on a Q-Sepharose column
pre-equilibrated with 50 mMNaOAc applying a gradient of 2 M
NaCl in 50 mM NaOAc. Fractions containing the pure product
were combined and dialyzed three times with Millipore water
using dialysis tubing with 1-kDa cut-off (Spectrum). Quantifi-
cation was performed by UV absorbance at 260 nm. Sequences
of the ODN prepared in this study were CpG, 5-TCCAT-
GACGTTCCTGACGTT-3; GpC, 5-TCCATGAGCTTCC-
TGATG-3.
Maleimidopropionoyl PeptidesMal-OVA247–264
andMal-OVA247–264A5K
Fmoc-deprotected peptide resin (200 mg, 30 mol) was sus-
pended in 2 ml of NMP, and 3-maleimidopropionic acid (5 eq,
250 mol, 42.2 mg), HCTU (5 eq, 250 mol, 103.2 mg), and
N,N-diisopropylethylamine (5 eq, 250mol, 42l) were added
subsequently. The mixture was shaken for 2 h after which the
resin was filtered, washed with NMP, dichloromethane, and
dried. A 2,4,6-trinitrobenzenesulfonic acid test indicated com-
plete coupling. The products were processed as described
under “Peptide Synthesis.”
ODN-Peptide Conjugates
For CpG-OVA247–264, 3-disulfide modified CpG-SS-pro-
pyl-OH (266 nmol) was converted to 3-SH-modified CpG-SH
overnight with dithiothreitol (DTT)-containing buffer (35 mg
of DTT, 26 mg of NaOAc3H2O, 1 ml of water). Dithiothreitol
was removed from themixture using a PD-10 desalting column
(Amersham Biosciences) that was pre-equilibrated with 25 ml
of a 50 mM phosphate buffer (25 mM Na2HPO4, 25 mM
NaH2PO4, 1 mM EDTA in water, continuously degassed with
helium. Filtrate (3.25ml) was directly transferred to a tube con-
taining 5 mg of maleimidopropionyl peptide Mal-OVA247–264.
The resulting solution was sonicated and placed under blanket
of argon. The tube was sealed and shaken for 2 days at room
temperature. The mixture was purified over a Superdex 75 gel
filtration columnusing isocratic elutionwith 0.15M triethylam-
monium acetate. Fractions containing the product were col-
lected and lyophilized. Excess triethylammonium acetate was
removed by lyophilization fromwater (3 times). Quantification
wasperformedbyUVabsorbance (260nm).CpG-OVA247–264A5K
and GpC-OVA247–264 were prepared as described for CpG-
OVA247–264 starting from the corresponding ODNs and male-
imidopropionyl peptides.
Lipopeptides
For Pam3CysSK4-OVA247–264, Fmoc-deprotected peptide
resin (300 mg, 45 mol) was suspended in 1.4 ml or 1:1 NMP/
dichloromethane. Pam3Cys-OH (91 mg, 2 eq, 100 mol) and
PyBOP (benzotriazole-1-yl-oxytrispyrrolidinophosphonium
hexafluorophosphate; 80 mg, 3 eq, 150 mol) were added.
N,N-Diisopropylethylamine (30 l, 175 mol) was added in
twoportions of 15l with an interval of 15min, and themixture
was shaken for 4 h.4 The resin was washed with NMP and
dichloromethane and dried. A 2,4,6-trinitrobenzenesulfonic
acid test indicated complete coupling. The product was cleaved
from the resin as described under “Peptide Synthesis,” dis-
solved in t-butyl alcohol/ACN/H2O (1:1:1), and purified on an
Alltima CN column (10  250 mm, 5-m particle size) with a
gradient of A to B; C was kept isocratic at 10% (A, 1:1 CH3OH/
H2O; B, ACN; C, 1% trifluoroacetic acid in 9:1 CH3OH/H2O).
Pam3CysSK4-OVA247–264A5K and Pam3CysSK4C-OVA247–264
were prepared and purified as described above for
Pam3CysSK4-OVA247–264 starting from the corresponding
peptide resins.
Fluorescently Labeled Peptides and Conjugates
[Alexa488]OVA247–264—Fmoc-deprotected peptide resin
(100 mg, 15 mol) was treated twice with 2 ml of a capping
reagent (0.5 M Ac2O, 0.125 M N,N-diisopropylethylamine in
NMP).A2,4,6-trinitrobenzenesulfonic acid test indicated com-
plete acetylation. The cleaved and purified peptide (1 mg) was
dissolved into 50 l of buffer (300 mM NaHCO3 in 30% aceto-
nitrile/water), andAlexa Fluor 488 carboxylic acid succinimidyl
ester (0.3 mg) was added. Another 50 l of buffer was added,
and the mixture was shaken overnight. The product was puri-
fied by reverse phase HPLC (see “General Methods”).
CpG-[Alexa488]OVA247–264 and GpC-[Alexa488]OVA247–264—
Conjugate CpG-OVA247–264 (296 nmol) or GpC-
[Alexa488]OVA247–264 (296 nmol) was dissolved in 50 l of
buffer (300 mM NaHCO3, 30% ACN in H2O), and Alexa Fluor
488 carboxylic acid succidinimidyl ester (1.0 mg) was added.
The bright green mixture was shaken overnight. The mixture
was diluted 5 times with H2O before being subjected to reverse
phase HPLC purification. (Alltima C18, gradient of A to B; C
was kept isocratic at 10%; A, H2O; B, ACN; C, 100 mM aqueous
NH4OAc).
Pam3CysSK4-C[BDP-FL]OVA247–264—Lipopeptide Pam3-
CysSK4C-OVA247–264 (0.46 mol, 1.69 mg) and BODIPY-FL
N-(2-aminoethyl)maleimide were transferred to a vial contain-
ing 0.5 ml of 50mM phosphate buffer (25mMNaH2PO4, 25mM
Na2HPO4, 1 mM EDTA in 2:1:1 H2O/ CH3OH /ACN). The
mixture was sonicated and shaken for 60 h under argon. The
4 The use of a large excess of N,N-diisopropylethylamine (4 eq relative to
Pam3Cys-OH) proved to be detrimental for the purity of the product as
judged by liquid chromatography/mass spectroscopy analysis.
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mixture was diluted 5 times with 40:30:30 H2O/ACN/t-butyl
alcohol, 1% trifluoroacetic acid before being subjected to
reverse phase HPLC purification as described for
Pam3CysSK4C-OVA247–264.
SK4-C[BDP-FL]-OVA247–264—SK4-C[BDP-FL]-OVA247–264
was synthesized as described for Pam3CysSK4-C[BDP-
FL]OVA247–264 using 50 mM phosphate in 3:2 H2O/ACN as a
ligation buffer and SK4-C-OVA247–264 as the peptide substrate.
Pam3CysSK4-C[Alexa488]OVA247–264 was synthesized as
described for Pam3CysSK4-C[BDP-FL]OVA247–264 usingAlexa
Fluor 488 C5 maleimide as the reactive dye.
IL-12p40 Enzyme-linked Immunosorbent Assay—DCs (4 
104) were plated into a 96-well round bottom plate and incu-
bated for 24–48 h with the compounds indicated in the legend
to Fig. 1. Supernatants were harvested and tested for IL-12 p40/
p70 content using a standard sandwich enzyme-linked immu-
nosorbent assay as previous described (23).
Confocal Microscopy
DCswere plated out into glass-bottomPetri dishes (MatTek)
2 days before the experiment. Cells were incubated either with
the fluorescence-labeled TLR-L peptide conjugate or the fluo-
rescence-labeled peptide at 37 °C for different time periods at
the concentrations indicated in the figure legends. In some
experiments, as indicated, cells were coincubated with 1 M
Lysotracker for 5 min to stain endosomal/lysosomal compart-
ments. In experiments with inhibitors, cells were preincubated
for 30 min either with 50 MMDC or 10 g/ml filipin followed
by extensively washing before incubation with the TLR-L con-
jugate either alone (pretreatment) or in the presence of inhibi-
tors (coincubation). Cells were then washed and imaged using
an inverted Leica SP2 confocal microscope. Dual color images
were acquired by sequential scanning, with only one laser line
per scan to avoid cross-excitation. The images were processed
using the software program ImageJ.
Flow Cytometry
For analyzing the effect of the different compounds on den-
dritic cell phenotypic profile, DCs were incubated with the dif-
ferent compounds at a final concentration of 1 M for 48 h.
Subsequently, cells were harvested, resuspended in fluores-
cence-activated cell buffer (phosphate-buffered saline, 0.1%
bovine serum albumin), and incubated for 20 min with the
following panel of monoclonal antibodies: fluorescein isothio-
cyanate-anti-CD86 (clone GL-1), phycoerythrin-anti-I-Ab
(clone M5/114 15.2), phycoerythrin- anti-CD40 (clone 3/23),
allophycocyanin-anti-Kb (24). Cells were washed twice and
fixed with 0.5% paraformaldehyde before being subjected to
flow cytometry measurements.
MHCClass I-restricted Antigen Presentation Assay
DCs were incubated for 2 h (unless stated otherwise in the
legends to Figs. 6 and 8) with 1) the parent peptide (DEVS-
GLEQLESIINFEKLAAAAAK, OVA247–264A5K, or DEVS-
GLEQLESIINFEKL, OVA247–264), 2) the peptide conjugate, or
3) the mixture of the parent peptide and the Pam3CySK4 or
CpG at the indicated concentrations. Cells were washed five
times withmedium before the T-cell hybridoma B3Z cells were
added and incubated for 16h at 37 °C.
Antigen presentation of the ovalbumin cytotoxic T-cell
epitope SIINFEKL (OVA257–264) inH-2Kbwas detected by acti-
vation of B3Z cellsmeasured by a colorimetric assay using chlo-
rophenol red--D-galactopyranoside as substrate to detect lacZ
activity in B3Z lysates, as described (23).
In some experiments cells were preincubated for 30minwith
titrated amounts of epoxomicin ranging from 0.01 to 10 M
epoxomicin or with 3 mM NH4Cl or preincubated for 60 min
with titrated amounts of monodansylcadaverine (25–50M) or
with filipin (10–20 g/ml) before adding the peptide com-
pound still in the presence of the inhibitors. Cell viability was
confirmed by tryphan blue exclusion at the indicated concen-
tration range of inhibitors.
Priming of Endogenous Naı¨ve CD8 T-cells
To determine the endogenous CTL response, five nmol of
the different compounds were injected s.c. into naı¨ve C57BL/6
mice. After 10 days spleen cells were stimulated in vitro by
plating 10  106 splenocytes with 1  106 mytomycin C
(Kyowa)-treated (50 g/ml for 1 h at 37 °C) and -irradiated
(4000 rads) EG7 cell line (EL4-OVA) in the absence of addi-
tional cytokines. After 7 days viable splenocytes were isolated
over a Ficoll gradient and stained for H-2Kb tetramer (TM)-
OVA257–264, CD8b2 (clone 53-5.8) and propidium iodide to
exclude dead cells as described previous (23).
Intracellular Cytokine Staining
An aliquot of spleen cells after re-stimulation and Ficoll puri-
fication (see above) were subjected to stimulation in vitro with
or without 1 g/ml OVA257–264 peptide (H2-Kb restricted
SIINFEKL) overnight in the presence of GolgiPlug (BD Pharm-
ingen). Cells were then washed twice with fluorescence-acti-
vated cell sorter buffer and stained with phycoerythrin-conju-
gated monoclonal rat anti-mouse CD8b2 antibody. Cells were
subjected to intracellular cytokine staining using the Cytofix/
Cytoperm kit according to themanufacturer’s instructions (BD
Pharmingen). Intracellular interferon- was stained with allo-
phycocyanin-conjugated rat anti-mouse interferon-. All anti-
bodies were purchased from BD Pharmingen. Flow cytometry
analysis was performed using FACSCalibur with CELLQuest
software (BD Biosciences). Splenocytes without peptide stimu-
lation were used as a negative control.
In Vivo Uptake Studies
To monitor the uptake of the TLR-L-conjugated peptides
and the free peptide in vivo, mice were injected s.c. either with 5
nmol of Alexa488 Fluor-labeled CpGconjugated peptide, 5
nmol of BODIPY-FL Pamconjugated peptide, CpG mixed
with Alexa488 Fluor-labeled peptide, or Pam mixed with
BODIPY-FL-labeled peptide. Three days later mice were sacri-
ficed, and a single cell suspension of the draining lymph nodes
was stained for CD11c (clone HL3) before being subjected to
flow cytometry analysis.
RESULTS
To study the uptake, trafficking, and processing of two dis-
tinct TLR-ligand peptide conjugates in dendritic cells forMHC
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class I presentation to CD8 cytotoxic T-lymphocytes, we
selected the TLR9 ligand CpG and the TLR2 ligand
Pam3CysSK4 (Pam) based on the fact that these two ligands
interact with two distinct receptors located either in the endo-
somal compartment (TLR9) or on the plasma membrane
(TLR2). As a model antigen wemade use of peptides contain-
ing the CTL epitope (SIINFEKL, designated OVA257–264)
derived from the ovalbumin protein. Two different peptide
length variants were synthesized, an extended peptide that
required proteasome-dependent processing on both the N
and C terminus to release the CTL epitope (DEVS-
GLEQLESIINFEKLAAAAAK) designated OVA247–264A5K,
and a shorter peptide, of which C-terminal processing by the pro-
teasome is not required (DEVSGLEQLESIINFEKL), designated
OVA247–264. For example, peptide OVA247–264A5K conjugated to
Pam3CysSK4 is designated as PamOVA247–264A5K.
Crucially, all of our compounds (listed in Table 1) are pro-
duced synthetically and are, therefore, chemically well defined,
of high purity, and of constant quality, avoiding potential con-
tamination with other TLR ligands such as LPS, which com-
monly occur in purified TLR ligand preparations.
Robust Induction of Naı¨ve CD8-specific T-cells Mediated by
the Conjugates—To establish the quality of our generated TLR-
L-peptide conjugates, we first investigated the induction of an
endogenous T-cell response following s.c. injection of either
TLR-L-conjugated peptide or free peptide into naı¨ve C57BL/6
mice. After 10 days, the induction of OVA247–264-specific
CD8 T-cells was analyzed. As is shown in Fig. 1A, the magni-
tude of the OVA257–264-specific T-cell response induction by
either CpGOVA247–264A5K or PamOVA247–264A5K was sig-
nificantly higher than that in mice injected with non-conju-
gated OVA247–264A5K peptide mixed together with either free
CpG or free Pam. To address whether the induction of specific
T-cells depended on activation of the DCs, we injected
GpCOVA247–264 conjugate, which is a non-stimulatory oligo-
nucleotide, as shown by its lack of capacity to induce IL-12
production by DCs (Fig. 1C). Injection of the GpCpeptide
conjugate into naı¨ve mice led to a significantly lower induction
of specific CD8 T-cells than of CpGconjugated peptide but
was still as high as the response obtained aftermixing of peptide
with the CpG (Fig. 1A). Importantly, only when a stimulatory
TLR-L conjugate was given, were the majority of CD8 T-cells
able to produce interferon- (Fig. 1B), indicating that signaling
via the TLR is essential for the generation of large numbers of
functional T-cells in vivo. These results suggest that the
enhanced induction of specific T-cells is primarily the result of
efficient delivery of the TLR-L-conjugated peptide into the
antigen-presenting cell.
TLR Conjugates Activate Dendritic Cells—Next we ana-
lyzed the ability of the different conjugates to induce matu-
ration of DCs. As evident from Table 2, increased surface
marker expression of CD40, CD86, MHC I, and MHC II was
observed in dendritic cells after treatment with the different
TLR-L conjugates to a similar extent as the free TLR-Ls. To
confirm the involvement of the TLRs in DC activation, we
isolated bone marrow-derived dendritic cells (BMDCs) from
wild type (WT) mice, TLR2-deficient mice, and TLR9-defi-
cient mice and stimulated these cells with the different con-
jugates followed by phenotypic characterization by staining
for different surface markers associated with DC maturation
(25). No up-regulation of the cell surface markers CD86 and
MHC class II was detected when BMDCs from TLR2-defi-
cient mice or TLR9-deficient mice were stimulated with
Pamconjugated peptide or CpGconjugated peptide,
respectively (Fig. 2). This impaired up-regulation was not
due to a general defect in the maturation signaling pathway,
because stimulation with LPS could induce up-regulation of
CD86 and MHC II in BMDCs derived from both TLR2- and
TLR9-deficient mice to a similar extent as observed for
BMDCs derived from wild type mice. Taken together, these
results demonstrate that the conjugates are as effective as
free TLR ligand in activating the DCs and show that the
expression of the cognate TLR is required for activation of
DCs by the TLR-L-peptide conjugates.
Efficient Uptake of CpG- and Pam-conjugated Antigen Pep-
tides by Dendritic Cells—Having demonstrated that TLR sig-
naling was important for DC activation and priming of T-cells,
we decided to compare the downstream cellular mechanism
used by the two types of TLR-L with respect to uptake, routing,
andcellular processing.Therefore, the efficiencyof antigenuptake
of conjugated versus non-conjugated peptide by DCs was deter-
mined. DCs were incubated with either Pamconjugated pep-
tide or free peptide. Both compounds were labeled with a flu-
orophore (attached on the peptide backbone), which allowed us
to monitor the internalization of these compounds by confocal
microscopy analysis. Introduction of the fluorophore (either
TABLE 1
List of compounds generated
The bold and underlined residues were used to couple the indicated fluorophores.
Abbreviation TLR ligand Peptide Fluorophore
OVA257–264 SIINFEKL
OVA247–264 DEVSGLEQLESIINFEKL
OVA247–264A5K DEVSGLEQLESIINFEKLAAAAAK
CpG-OVA247–264 CpG DEVSGLEQLESIINFEKL
CpG-OVA247–264A5K CpG DEVSGLEQLESIINFEKLAAAAAK
GpC-OVA247–264 GpC DEVSGLEQLESIINFEKL
Pam3CysSK4-OVA247–264 Pam3CysSK4 DEVSGLEQLESIINFEKL
Pam3CysSK4-OVA247–264A5K Pam3CysSK4 DEVSGLEQLESIINFEKLAAAAAK
Alexa488OVA247–264 Ac-DEVSGLEQLESIINFEKL Alexa488
SK4-CBDP-FL-OVA247–264 SKKKKCDEVGLEQLESIINFEKL Bodipy-FL
CpG-Alexa488OVA247–264 CpG DEVSGLEQLESIINFEKL Alexa488
GpC-Alexa488OVA247–264 GpC DEVSGLEQLESIINFEKL Alexa488
Pam3CysSK4-CAlexa488OVA247–264 Pam3CysSK4 CDEVSGLEQLESIINFEKL Alexa488
Pam3CysSK4-CBDP-FLOVA247–264 Pam3CysSK4 CDEVSGLEQLESIINFEKL Bodipy-FL
Internalization and Routing of TLR Ligand-Peptide Conjugates
JULY 20, 2007•VOLUME 282•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 21149
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Alexa488 or BODIPY-FL) into the conjugates did not alter
the ability of the conjugates to activate DCs as comparable
levels of the IL-12 cytokine were produced by the fluorescent
conjugates and the dark conjugates.5 As indicated by the
increased intensity of fluorescence inside the cells, the
Pamconjugated peptides were taken up far more efficiently
than the non-conjugated peptide (Fig. 3A). Interestingly, the
Pamconjugated peptide was found to accumulate in hot
spots (indicated by arrows in Fig. 3A), whereas a more diffuse
pattern was observed in DCs incubated with the peptide
alone. Quantification of the mean fluorescence intensity
(MFI) revealed a more than 4-fold higher fluorescence in
DCs incubated with the Pamconjugate compared with DCs
incubated with the peptide (Fig. 3B). Similarly,
CpGconjugated peptide was internalized more efficiently
than the unconjugated peptide by DCs (Fig. 3C). In addition,
the non-stimulatory GpCconjugate (MFI 63 7.3) was inter-
5 S. Khan, M. S. Bijker, J. J. Weterings, H. J. Tanke, G. J. Adema, T. van Hall, J. W.
Drijfhout, C. J. M. Melief, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov,
S. H. van der Burg, and F. Ossendorp, unpublished data.
FIGURE 1. Robust induction of naı¨ve CD8-specific T-cells mediated by the TLR-L conjugates. A, naı¨ve C57/B6mice were injected with either Pammixed
withOVA247–264A5K (Pammixedw. peptide), PamOVA247–264A5K (Pamconjugate), CpGmixedwithOVA247–264A5K (CpGmixedw. peptide), CpGOVA247–264A5K
(CpG conjugate), or GpCOVA247–264 (GpCconjugate). After stimulation in vitro, cells were analyzed for the presence of CD8b2 cells capable of interacting
with H-2Kb-OVA257–264 tetrameric complexes. The y axis displays the percentages of tetrameric-positive cells out of total CD8b2 cells. The percent of
tetrameric CD8b2 cells (1%)of thenaı¨vemice (phosphate-buffered saline (PBS) injectiononly) hasbeen subtracted fromall the values. The right-handpanel
shows a representative FACS plot; cells were gated on CD8, and the percentages given in the top of the right quadrant are the percentages of tetramer-
positive cells of total CD8 T cells. Unpaired Student’s t test error: *, p	 0.04; **, p	 0.0006; ***, p	 0.001; n.s., not significant. B, interferon- (IFN) production
in specific T-cells wasmeasured as described under “Experimental Procedures.” Shown are results gated on CD8 events. PammixedwithOVA247–264A5K (Pam
mixed w. peptide), PamOVA247–264A5K (Pamconjugate), CpG mixed with OVA247–264A5K (CpG mixed w. peptide), CpGOVA247–264A5K (CpGconjugate), or
GpCOVA247–264 (GpCconjugate). Unpaired Student’s t test error: *, p	 0.05; **, p	 0.001; ***, p	 0.0007; n.s., not significant. Experiments were conducted
with five mice per group. C, BMDCs were incubated either with CpGOVA247–264A5K (black bars) or GpCOVA247–264 (white bars) for 48 h. Supernatant was
harvested, and the concentration of IL-12p40was determined as outlined under Experimental Procedures.“ Results are themeans of triplicates S.E. Data are
representative of three independent experiments.
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nalized to a similar extent as the stimulatory CpGconjugate
(MFI 72 9.1) (Fig. 3D).
These comparisons indicate that the fluorescent TLR-L con-
jugates are taken upmuchmore efficiently by DCs than uncon-
jugated peptides in vitro. To examine the uptake efficiency in
vivo, mice were injected with either Alexa488 Fluor-labeled
CpGconjugate or peptide labeled with Alexa488 Fluor mixed
with darkCpG.Three days later draining lymphnode cells were
stained for the DC surface marker CD11c. In line with the in
vitro results, a significantly higher proportion of CD11c cells
had taken up the CpGconjugated peptide (2.5%) when com-
pared with the population of DCs that ingested unconjugated
peptide (0.3%) or non-injected mice (0.1%; Fig. 3E). A similar
tendency was observed upon comparison of BOPIPY-FL-la-
beled Pamconjugate with peptide labeled with BODIPY-FL
mixed with dark Pam (Fig. 3F). Collectively, these results indi-
cate that it is the covalent linking of the peptide to the TLR-L
that is responsible for the enhanced uptake by the DCs.
Conjugates Translocate to the Endosomal/Lysosomal Com-
partment Independently of TLR Expression—Our antigen
uptake studies revealed that also the TLR9-L conjugate was
taken up more efficient despite that TLR9 is not surface-ex-
pressed. Therefore, to evaluate the relevance of TLR expression
for the enhanced uptake, BMDCs purified fromWT, TLR2
/
,
and TLR9
/
 mice were incubated with Alexa488 Fluor-la-
beled TLR-L conjugates. As shown in Fig. 4, A and C, BMDCs
from TLR9
/
mice internalized CpGconjugates to a similar
extent as BMDCs from wild type mice, as reported previously
(2).
Surprisingly, similar experiment carried out with
Pamconjugate and BMDCs from WT mice and TLR2
/

mice showed that also the Pam conjugate, despite the fact that
the receptor for Pam (TLR2) is located on the cell surface (1,
26), were internalized equally well by both types of DCs (Fig. 4,
B and D).
To monitor the intracellular localization of the conjugates,
we performed a co-localization study between the conjugates
(green) and the endosomes (red). As seen in Fig. 4E, both the
CpG and Pamconjugates are co-localized partially with an
endosomal tracker (Lysotracker) in a pattern characteristic for
the endosomal vehicles. Moreover, no overall difference in the
uptake kinetic or in the trafficking of the compounds could be
detected when comparing BMDCs fromwild typemice tomice
deficient for either TLR9 or TLR2 expression.5 These results
indicate that TLR expression is not required for uptake and that
the conjugate re-locates to the endosomal compartment.
Conjugation of Peptide Leads to Pronounced Enhancement in
Antigen Presentation in Vitro—Having established that the
conjugates were taken up much more efficiently than the free
peptide harboring the OVA CTL epitope SIINFEKL, we next
addressed the effect of conjugation of peptide toTLR-L on anti-
gen presentation. DCs were loaded with either the
CpGconjugated peptide, Pamconjugated peptide, the CpG
FIGURE 2. TLR-dependent DC activation. A, BMDCs from eitherWT or TLR9-deficientmice (TLR9 KO) were incubated either with 1M CpGOVA247–264A5K or
E. coliLPS (10g/ml) for 48h.Cellswere stainedwithCD86orMHC II antibodies asdescribedunder ”Experimental Procedures“ and subjected to flowcytometry
analysis. B, BMDCs from eitherWT or TLR2-deficientmice (TLR2 KO) were incubated either with 1M PamOVA247–264A5K or E. coli LPS (10g/ml) for 48 h, and
cells were treated as stated under A.
TABLE 2
Cell surface marker expression after TLR-L- conjugate-induced
maturation of dendritic cells
Dendritic cells were incubated for 48 h in the presence of 1 M concentrations of
either OVA247–264 (peptide), CpG, CpG-mixed OVA247–264 (CpG mixed with pep-
tide), CpG  OVA247–264 (CpGconjugate), Pam, Pam mixed with OVA247–264
(Pammixed with peptide), PamOVA247–264 (Pamconjugate), or with E .coli LPS
(10 g/ml). Cells were stained with specific antibodies as described under “Experi-
mental Procedures” and subjected to flow cytometry analysis. Indicated are the
mean fluorescence intensities of positive cells. The results were obtained from a
single experiment and are representative of four similar experiments. ND, not done.
Treatment Mean fluorescenceCD40 CD86 MHC I MHC II
Untreated 8 21 923 277
Peptide 8 22 ND 271
CpG 59 136 3421 512
CpG mixed with peptide 48 134 ND 903
CpGconjugate 71 132 3229 725
Pam 16 38 ND 327
Pam mixed with peptide 18 40 ND 346
Pamconjugate 14 35 1348 329
LPS 46 137 3572 576
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FIGURE 3. Efficient antigen uptake mediated by the TLR-L conjugates. A, confocal images of the dendritic cell line D1 incubated for 15 min with either
BODIPY-FL labeled PamOVA247–264 (Pamconjugate) or BODIPY-FL-labeled peptide OVA247–264 (Peptide) at different concentrations. Arrows indicate accu-
mulation of Pamconjugates. B, quantification of MFI of fluorescence inside numbered cells selected from A. C, DCs were incubated with either Alexa488
Fluor-labeled CpGOVA247–264 (CpGconjugate), PamOVA247–264 (Pamconjugate), or OVA247–264 peptide for 30 min; all compounds were used at 2.5 M.
D, DCs were incubated with either Alexa488 Fluor-labeled CpGOVA247–264 (CpGconjugate) or GpCOVA247–264 (GpCconjugate) for 30 min at a final
concentration of 5 M. All scale bars in A–D are 20 m. E, mice were injected s.c. with either Alexa488 Fluor-labeled peptide OVA247–264 mixed with CpG or
Alexa488 Fluor-labeled CpGOVA247–264. 72 h later mice were sacrificed and drained lymph node cells were stained for CD11c. The y axis displays the
percentages of Alexa488-positive cells out of total CD11c cells. F, mice were injected s.c. with either BODIPY-FL-labeled peptide OVA247–264 mixed with Pam or
BODIPY-FL labeled PamOVA247–264. 72 h later mice were sacrifices, and drained lymph node cells were stained for CD11c. The y axis displays the percentages
of BODIPY-FL-positive cells out of total CD11c cells. Experiments were conducted twice with similar results.
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or Pam mixed with the peptide, or the peptide alone (Fig. 5, A
andB) before incubationwith the peptide-specific T-cell hybri-
doma B3Z cells that recognize the H-2Kb, SIINFEKL CTL
epitope (27). As the concentration
of the compounds decreased, anti-
gen recognition was rapidly lost
when DCs were incubated either
with the peptide alone or with the
peptide mixed with CpG but not
when the CpGconjugated peptide
was used. This indicates that the
conjugation of peptides to TLR-L
enhances antigen presentation (Fig.
5A). Likewise, an increased antigen
presentation was observed for the
Pamconjugated peptide (Fig. 5B).
In this case the difference in antigen
presentation between conjugate
and non-conjugate was even more
prominent. Incubation with a mix-
ture of free TLR-L (Pam or CpG)
and the peptides resulted in a
decreased antigen presentation by
DCs when compared with loading
with peptide alone or with conju-
gated peptide. This might be related
to decreased uptake, since it has
previously been reported that the
endocytotic capacity of DCs
declines upon encountering matu-
ration signals (28, 29).
To gain insight in the kinetics of
antigen presentation, DCs were
incubated for various time periods
with either TLR-L-conjugated
peptide, peptide mixed with
TLR-L, or peptide alone. As shown
in Fig. 5, C and D, it required
24–48 h of continuous presence
of peptide mixed with CpG or Pam
or of peptide alone to reach the
level of antigen presentation
acquired already after 2 h of incu-
bation with the conjugated pep-
tide, as measured by an equal
ability to stimulate the peptide-
specific B3Z hybridoma T-cells.
Thus, conjugation greatly improves
the swiftness of presentation of anti-
gen by DCs for stimulation of
T-cells.
The confocal microscopy results
indicated that uptake of the conju-
gates occurred independently from
the expression of the respective
TLRs. Therefore, we next evaluated
the impact of TLR expression upon
antigen presentation. To this end
BMDCs from WT, TLR2
/
, and TLR9
/
 mice loaded with
the conjugates were incubated in vitro together and subse-
quently incubated with the peptide-specific T-cell hybridoma
FIGURE 4.TLR conjugates translocate to the endosomal compartment independently of TLR expression.
A, BMDCs from wild type mice or TLR9-deficient mice were incubated for 30 min with Alexa488 Fluor-labeled
CpGOVA247–264 (5 M). B, BMDCs from wild type mice or TLR2-deficient mice were incubated for 30 min with
Alexa488 Fluor PamOVA247–264 (2.5 M). Scale bars in A and B are 15 m. C, quantification of uptake of
CpGconjugate in BMDCs fromWTandTLR9-deficientmice (TLR9 KO) was doneon10 randomcells selected from
similar pictures as depicted in A. D, quantification of uptake of the Pamconjugate in BMDCs fromWT and TLR2-
deficientmice (TLR2KO)wasperformedon10 randomcells selected fromsimilarpicturesasdepicted inB.E, BMDCs
were incubate with Alexa488 Fluor-labeled CpGOVA247–264 (5 M) or PamOVA247–264 (2.5 M) in combination
with 1 M Lysotracker-DND99 before imaging. Images were acquired by sequential scanning, with only one laser
line per scan to avoid cross-excitation. Scale bars are 10mand 5m in the enlarged images in the right panel.
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B3Z cell line. In line with the confocal uptake studies, BMDCs
derived fromWT or the TLR2- or TLR9-deficient mice strains
were recognized to the same extent (Fig. 6, A and B).
Disruption of Clathrin Formation and Caveolae Clustering
Blocks Antigen Presentation of TLR-L Conjugates—DCs can
take up exogenous antigens via different mechanisms such as
clathrin-mediated endocytosis, fluid phase endocytosis, and
macropinocytosis (30). To define the pathways by which the
TLR-L-peptide conjugates were internalized, DCs were pre-
treated with different inhibitors before loading with the TLR-L
conjugates. Macropinocytosis inhibitor 5-(N,N-dimethyl)-
amiloride (29) had no effect on antigen presentation.5 On the
other hand pretreatmentwith filipin, a sterol binding agent that
disrupt caveolae structures (31) and thereby lipid-raft forma-
tion, reduced antigen presentation of both Pamconjugates as
well as CpGconjugates in a dose-dependentmanner, whereas
antigen presentation of the CTL epitope OVA257–264 was only
marginal affected (Fig. 6C). Because lipid raft formation is
involved both in clathrin-dependent endocytosis as well as
caveolae-dependent internalization (32), we analyzed the
impact of MDC, a specific inhibitor of clathrin formation (33,
34), upon antigen presentation. Interestingly, whereas antigen
presentation of CpGconjugated peptides was not affected by
MDC, antigen presentation of Pamconjugated peptides was
abrogated in a dose-dependent fashion (Fig. 6D). To further
explore the distinct uptake mechanisms used by the two types
FIGURE 5. TLR-L conjugates strongly enhance antigen presentation. A, the dendritic cell line, D1, was incubated with either the OVA247–264 peptide (gray
bars), theOVA247–264peptidemixedwithCpG (white bars), or CpGconjugated toOVA247–264 (blackbars). After 2h cellswerewashed, andB3Zcellswere added
and co-cultured for 24 h before their activation wasmeasured. B, D1 cells were incubated under the same conditions as indicated under A but in the presence
of either the OVA247–264 peptide (gray bars), OVA247–264 peptide mixed with Pam (white bars), or Pam-conjugated OVA247–264 peptide (black bars). Results are
the means of triplicates S.E. BMDCs were incubated for various time periods with either OVA247–264A5K (gray bars) CpG mixed with OVA247–264A5K peptide
(white bars) orCpGOVA247–264A5K (blackbars) (C) orwithOVA247–264A5Kpeptide (graybars), PammixedwithOVA247–264A5K (white bars), or PamOVA247–264A5K
(black bars) (D) before co-culturing with B3Z T-cell hybridoma as outlined under ”Experimental Procedures.“
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of conjugates, confocalmicroscopywasperformedonDCs treated
with the two inhibitors. As evident from Fig. 7, both MDC and
filipin abolished the internalization of the Pam conjugate in terms
of mean fluorescence per cell, whereas inhibition of clathrin for-
mation had a less pronounced effect on internalization of the
CpGconjugate (Fig. 7C).On the other hand, inhibition of caveo-
lin formation by filipin reduced the mean fluorescence of cells
incubated with the CpGconjugate. The selective effect of the
inhibitors was not due to a direct effect on one conjugate, as pre-
incubation of cells with the inhibitor followed by extensive wash-
ingbefore incubationwith the conjugates (indicated as preincuba-
tion in Fig. 7) in the absence of inhibitors led to similar results.
Thus, these results indicate that the two TLR-L conjugates are
internalized by distinct uptake receptors.
Antigen Presentation Depends upon Endosomal Acidifica-
tion, Proteasome Activity, and TAP Translocation—Next, we
examined the impact of different proteases upon antigen pres-
entation. To address this issue, we
made use of the C-terminal extended
peptides (OVA247–264A5K), which
require both N-and C-terminal
processing to release the SIINFEKL
CTLpeptide epitope. DCswere pre-
treated either with epoxomicin,
which inhibits the proteasome, or
NH4Cl, which increases the pH in
the acidic endosome/lysosome
environment and thereby inhibits
the proteases that depend on acidi-
fication (35–38) before incubation
with either of the conjugates. As evi-
dent from Fig. 8,A and B, whenDCs
were pretreated with the lysosomo-
tropic agent, NH4Cl, a decrease in
antigen presentation was seen rang-
ing from 45% inhibition for the
Pamconjugates to 70% for the
CpGconjugated peptide. Simi-
larly, inhibition of the proteasome
activity resulted in an overall
decrease in antigen presentation of
both the CpGconjugated and
Pamconjugated peptide (up to
50% inhibition) in a dose-dependent
manner (Fig. 8C). To ascertain that
the inhibitory effect observed was
not due to an overall decrease in the
surface expression of MHC class I,
DCs that had been pretreated with
either epoxomicin or NH4Cl were
incubated with the minimal CTL
epitope OVA257–264. As expected,
the inhibitors did not cause a major
affect upon antigen presentation of
exogenous loaded OVA257–264 pep-
tide (Fig. 8, B and C).
After proteasomal processing,
CTL peptide epitopes need to be
translocated into the luminal side of the endoplasmic reticulum
via the transporter complex TAP to be loaded onto MHC class
I molecules. To address the involvement of TAP for cross pres-
entation of the TLR-L conjugates, BMDCs from either wild
type mice or TAP-deficient mice were loaded with the TLR-L
conjugates or theminimalCTL epitopeOVA257–264. As evident
in Fig. 8D, antigen presentation of both the TLR2L and TLR9L
conjugates depended upon TAP activity, as the presentation
was abrogated in TAP-deficient mice. Importantly, antigen
presentation of the minimal CTL epitope OVA257–264 was not
affected in the TAP-deficient DCs, showing that the observed
TAP dependence of the conjugates was not due to an overall
reduced surface expression ofMHCclass I in theTAP-deficient
DCs. In contrast, when using BMDCs from mice deficient in
bothTAP and2-microglobulin expression (TAP
/
2m
/
)
completely lacking MHC class I surface expression (39), anti-
gen presentation was completely lost for all peptides (Fig. 8D).
FIGURE 6. Antigen presentation of TLR-L conjugates does not require TLR expression but is dependent
on receptor-mediated endocytosis. A, BMDCs fromwild typemice (black bars) or TLR9 deficient mice (white
bars) were incubated for 2 hwith CpGOVA247–264 andprocessed for antigenpresentation as described under
”Experimental Procedures.“ B, BMDCs fromwild typemice (black bars) or TLR2-deficientmice (white bars) were
incubated for 2 hwith PamOVA247–264 and processed for antigen presentation. C, DCs were left untreated or
were pretreated for 60 min with various concentrations of filipin or with various concentrations of MDC (D)
before the addition of 0.5M CpGOVA247–264A5K (gray bars), 0.5M PamOVA247–264A5K (white bars), or 0.01
M OVA257–264 (black bars). Cells were incubated with the peptides for 3 h in the presence of inhibitors before
beingprocessedasoutlinedunder ”Experimental Procedures.“ Actual optical density values inC in the absence
of filipin were: CpGconjugate, 0.5; Pamconjugate, 1.4; OVA257–264, 2.0. Actual optical density values in D in
the absence of MDC were: CpGconjugate, 0.5; Pamconjugate, 1.0; OVA257–264, 1.4. Background optical
density levels of cells incubated without peptides were below 0.1 in both experiments.
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Collectively, these results indicate that endosomal acidifica-
tion, proteasomal activity, and TAP translocation are required
for antigen presentation of the TLR-L peptide conjugates and
suggest that the peptide (conjugate)
translocates via the endosomal com-
partment into the cytosol where the
peptide undergoes proteasomal
processing before being loaded onto
MHC class I molecules in the endo-
plasmic reticulum.
DISCUSSION
In this study we analyzed the cel-
lular uptake and trafficking of two
distinct TLR ligand-antigen conju-
gates that ultimately lead to the
induction of an efficient CTL
response. Strikingly, one single s.c.
immunization with conjugate in
saline induced an impressive sys-
temic expansion of antigen-specific
CD8 T-cells (Fig. 1). Thus, conjuga-
tion resulted in a stronger systemic
response than what was observed
for the mixed vaccines.
Our immunofluorescence analy-
sis revealed that conjugates of both
types of TLR ligands were taken up
very efficiently compared with
unconjugated peptides (Fig. 3).
Internalization was a very rapid
process since uptake studies showed
that already within 15–30 min, the
major part of the conjugates could
be found in endosome/lysosome
compartments (Fig. 4).5 For this we
have used fluorescent conjugates;
these may have slightly different
properties from those of the
unmodified conjugates, which
could influence the uptake and
function. However, the fluorescent
conjugates induced DC maturation
to a similar extent as the unmodified
conjugates.5 In line with our find-
ings, CpG linked to fluorescein
isothiocyanate-labeled ovalbumin
protein was recently shown to
translocate to LAMP-1-positive
endosomal-lysosomal compartments
(10). Further support of enhanced
uptake mediated by the conjugates
was provided from our in vivo
uptake analysis, which revealed a
6–8-fold increase in uptake of
the CpG-conjugated peptide by
CD11c cells and a 2-fold increase
in uptake of the Pam-conjugated
peptide by CD11c cells compared with uptake of non-conju-
gated peptide (Fig. 3,E and F).We found that CpGconjugated
peptides were internalized independently from the expression
FIGURE 7. Effect of filipin andMDC on internalization of the TLR-L conjugates. DCs were left untreated or
pretreated for 30min with 10g/ml filipin before adding Alexa488-labeled CpGconjugate (A) or BODIPY-FL
labeled Pamconjugate (B) either in the presence of filipin (coincubation) or in the absence of filipin (pretreat-
ment) for 30 min at 37 °C before being subjected to confocal microscopy analysis. DCs were left untreated or
pretreated for 30 min with 50 M MDC before adding Alexa488-labeled CpGconjugate (C) or BODIPY-FL
labeled Pamconjugate (D) either in the presence of MDC (coincubation) or in the absence of MDC (pretreat-
ment) for 30 min at 37 °C before being subjected to confocal microscopy analysis. Shown is the mean fluores-
cence intensity per cell based on quantification of 10 random selected cells.
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of TLR9 and could also support antigen presentation in vitro
independently of TLR9 expression (Fig. 4). Accordingly, Wag-
ner and co-workers (2) showed that cross-presentation of
OVA-linked CpG occurred independently from TLR9 expres-
sion but that TLR9 expression nevertheless was essential for
activation of the DCs. At first sight these findings might seem
paradoxical; however, TLR9 are mainly expressed in the endo-
plasmic reticulum followed by recruitment to the endosomes
upon dendritic cell maturation (40).
Unexpectedly, considering the cell surface expression of
TLR2, we found that internalization of the Pamconjugate was
taken up independently from the expression of TLR2. BMDCs
isolated from TLR2-deficient mice internalized the
Pamconjugate to a comparable level as BMDCs from wild
type mice, and antigen recognition was unaffected in BMDCs
from TLR2-deficient mice. This could not be attributed to a
side effect mediated by the peptide
part, since TLR2-independent inter-
nalization was also observed when
incubating the cells with free Pam.5
Importantly, inhibition of clathrin-
dependent endocytosis or caveolae
formation abrogated both uptake
and antigen presentation of Pam
conjugates (Figs. 6 and 7), whereas
internalization of CpG conjugates
was independent of clathrin-coated
pits but dependent on caveolae for-
mation. These results indicate that
other (distinct) receptors than the
TLRs are involved in the uptake of
the TLR conjugates, although the
exact nature of these receptors
remains to be established. Other
TLR2 ligands have been reported to
be internalized independently from
the expression of TLR2. Outer
membrane protein A, a conserved
major component of the outer
membrane of Enterobacteriaceae
family that triggers cytokine pro-
duction in macrophages and DCs
(41), was recently shown to be inter-
nalized by the scavenger receptor
LOX-1 independently from the
expression of TLR2 (42). Moreover,
lipoteichoic acid has also been
reported to be internalized inde-
pendently from TLR2 expression
(43), although the receptor involved
in the uptake of lipoteichoic acid
still remains to be identified. There-
fore, the contribution of TLR2 and
other receptors expressed on the
cell surface to the uptake of Pamand
other TLR ligands remains to be
established.
Optimal presentation of the pep-
tide antigen cargo in the conjugates required endosomal acidi-
fication (Fig. 8), although it cannot be ruled out that the fusion
of early endosomal vesicleswith late endosomal vesicles is ham-
pered by the lysosomotropic agent NH4Cl (37, 44–46).These
results imply that endosomal proteases, such as cathepins (45,
47), might be involved in the processing of the TLR-L-peptide
conjugate. Furthermore, proteasomal cleavage was required
because proteasome inhibition greatly decreased antigen pres-
entation of the TLR-L conjugates (Fig. 8C). Because protea-
somes are mainly located in the cytosol (48, 49), our results
indicate that the peptide/conjugate, after being released in the
endosomal compartment, translocate to the cytosol to undergo
proteasomal processing (45). In this regard it was recently
reported that the translocon complex SEC61 could be involved
in facilitating the translocation of peptide from the endosomes
to the cytosol (50). Moreover, abrogation of translocation of
FIGURE 8. Antigen presentation depends upon endosomal acidification, proteasomal activity, and TAP
translocation.DCswere left untreated or pretreated for 60minwith various concentrations of 3mMNH4Cl (A)
and (B), or epoxomicin (C) before the addition of 0.5 M CpGOVA247–264A5K (squares), 0.5 M
PamOVA247–264A5K (triangles), or 0.01 M OVA257–264 (circles). Cells were incubated with the peptides for
3 h in the presence of inhibitors before being processed as outlined under ”Experimental Procedures.“
,
untreated; , treated with NH4Cl. Results are the means of triplicates S.E. D, BMDCs from WT mice,
TAP-deficient mice (TAP
/
), or mice deficient in TAP and 2-microglobulin (TAP
/
 2m
/
) were pre-
loaded either with CpG-conjugates, Pam-conjugate, or OVA257–264 before being processed as outlined
under ”Experimental Procedures.“
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peptides from the cytosol to the endoplasmic reticulum com-
pletely abrogated antigen presentation of both types of TLR-L-
peptide conjugates (Fig. 8D). Aside frombeing internalized effi-
ciently, we found that all of the TLR-L conjugates retained their
capacity to activate DCs to a comparable level as the free TLR-L
both in terms of production of the Th1-favoring cytokine,
IL-12,5 and up-regulation of DC maturation surface markers
(Table 2). Importantly, TLR expression was required for DC
activation, since BMDCs lacking TLR2 or TLR9 were not able
to up-regulate co-stimulatorymolecules upon stimulation with
either Pamconjugate or CpGconjugate, respectively (Fig.
2). In addition, conjugation of the non-stimulatory GpC oligo-
nucleotide to the peptide antigen resulted in inefficient CTL
priming (Fig. 1), showing that the DC activation of TLR-L pep-
tide conjugates is essential. Therefore, intracellular signaling of
TLR is crucially important for effective CTL priming by the
conjugates.
In summary, we demonstrate that well defined synthetic
TLR-L-peptide conjugates induce a robust and systemic
response of specific T-cells due to the combined action of
enhanced antigen uptake, improved MHC class I antigen pres-
entation, and dendritic cell maturation. Our data show that
targeting to two different TLRs requires a distinct uptake
mechanism independent of TLR expression but follows similar
trafficking and intracellular processing pathways leading to
optimal antigen presentation and T-cell priming. The chemical
properties of these conjugates, which ensure that the sameDCs
that take up the antigen receives simultaneously a proper mat-
uration signal, is likely to be themechanismbehind the superior
activity of the peptide conjugates. Accordingly, Medzhitov and
Blander (51) recently reported that synchronous entrance of
TLR-L and antigen enhanced MHC class II presentation,
although in their system antigen and TLR-L was delivered on
microspheres in a non-covalent manner. The collective fea-
tures of our TLR-L peptide conjugates together with their con-
venient manufacture and handling makes synthetic peptide-
TLR-ligand conjugates an attractive novel vaccine modality.
Acknowledgments—We thank Dr. M. Haks for critical reading the
manuscript and Dr. R. Sutmuller for assistance with generation of
TLR9
/
 bone marrow-derived dendritic cells.
REFERENCES
1. Kaisho, T., and Akira, S. (2004)Microbes Infect. 6, 1388–1394
2. Heit, A., Maurer, T., Hochrein, H., Bauer, S., Huster, K. M., Busch, D. H.,
and Wagner, H. (2003) J. Immunol. 170, 2802–2805
3. Miggin, S. M., and O’Neill, L. A. (2006) J. Leukocyte Biol. 80, 220–226
4. Riezman, H., Woodman, P. G., van Meer, G., and Marsh, M. (1997) Cell
91, 731–738
5. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S.
(2002) Annu. Rev. Immunol. 20, 621–667
6. Xiang, S. D., Scholzen, A.,Minigo, G., David, C., Apostolopoulos, V.,Mot-
tram, P. L., and Plebanski, M. (2006)Methods 40, 1–9
7. Yewdell, J. W., Reits, E., and Neefjes, J. (2003) Nat. Rev. Immunol. 3,
952–961
8. Schuurhuis, D. H., Laban, S., Toes, R. E., Ricciardi-Castagnoli, P., Klei-
jmeer, M. J., van der Voort, E. I., Rea, D., Offringa, R., Geuze, H. J., Melief,
C. J., and Ossendorp, F. (2000) J. Exp. Med. 192, 145–150
9. Heath, W. R., Belz, G. T., Behrens, G. M., Smith, C. M., Forehan, S. P.,
Parish, I. A., Davey, G. M., Wilson, N. S., Carbone, F. R., and Villadangos,
J. A. (2004) Immunol. Rev. 199, 9–26
10. Heit, A., Schmitz, F., O’Keeffe,M., Staib, C., Busch, D. H.,Wagner, H., and
Huster, K. M. (2005) J. Immunol. 174, 4373–4380
11. Horner, A. A., Datta, S. K., Takabayashi, K., Belyakov, I. M., Hayashi, T.,
Cinman, N., Nguyen, M. D., Van Uden, J. H., Berzofsky, J. A., Richman,
D. D., and Raz, E. (2001) J. Immunol. 167, 1584–1591
12. Shirota, H., Sano, K., Hirasawa, N., Terui, T., Ohuchi, K., Hattori, T.,
Shirato, K., and Tamura, G. (2001) J. Immunol. 167, 66–74
13. Tighe, H., Takabayashi, K., Schwartz, D., VanNest, G., Tuck, S., Eiden, J. J.,
Kagey-Sobotka, A., Creticos, P. S., Lichtenstein, L. M., Spiegelberg, H. L.,
and Raz, E. (2000) J. Allergy Clin. Immunol. 106, 124–134
14. Zeng, W., Ghosh, S., Lau, Y. F., Brown, L. E., and Jackson, D. C. (2002)
J. Immunol. 169, 4905–4912
15. Cho, H. J., Takabayashi, K., Cheng, P. M., Nguyen, M. D., Corr, M., Tuck,
S., and Raz, E. (2000) Nat. Biotechnol. 18, 509–514
16. Maurer, T., Heit, A., Hochrein, H., Ampenberger, F., O’Keeffe, M., Bauer,
S., Lipford, G. B., Vabulas, R. M., and Wagner, H. (2002) Eur. J. Immunol.
32, 2356–2364
17. Matyszak, M. K., Citterio, S., Rescigno, M., and Ricciardi-Castagnoli, P.
(2000) Eur. J. Immunol. 30, 1233–1242
18. Winzler, C., Rovere, P., Rescigno, M., Granucci, F., Penna, G., Adorini, L.,
Zimmermann, V. S., Davoust, J., and Ricciardi-Castagnoli, P. (1997) J. Exp.
Med. 185, 317–328
19. Sanderson, S., and Shastri, N. (1994) Int. Immunol. 6, 369–376
20. Moore, M. W., Carbone, F. R., and Bevan, M. J. (1988) Cell 54, 777–785
21. Chan, W. C., andWhite, P. D. (2000) in Fmoc Solid Phase Peptide Synthe-
sis: A Practical Approach (Chan, W. C., and White, P. D., eds) pp. 41–74,
Oxford University Press, New York
22. Grandas, A., Marchan, V., Debethune, L., and Pedroso, E. (2003) in Cur-
rent Protocols inNucleic Acid Chemistry (Beaucage, S. L., Bergstrom,D. E.,
Glick, G. D., Jones, R. A., eds) pp. 4.22.1–4.22.54, JohnWiley & Sons, Inc.,
New York
23. Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J. J.,
Sedlik, C.,Melief, C. J., Verbeek, J. S., andOssendorp, F. (2002) J. Immunol.
168, 2240–2246
24. Stukart, M. J., Boes, J., and Melief, C. J. (1984) J. Immunol. 133, 24–27
25. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J.,
Pulendran, B., and Palucka, K. (2000) Annu. Rev. Immunol. 18, 767–811
26. Kaisho, T., and Akira, S. (2001) Acta Odontol. Scand. 59, 124–130
27. Karttunen, J., and Shastri, N. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,
3972–3976
28. Mellman, I., and Steinman, R. M. (2001) Cell 106, 255–258
29. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. (1995) J. Exp.Med.
182, 389–400
30. Steinman, R. M., Inaba, K., Turley, S., Pierre, P., and Mellman, I. (1999)
Hum. Immunol. 60, 562–567
31. Rothberg, K. G., Heuser, J. E., Donzell,W.C., Ying, Y. S., Glenney, J. R., and
Anderson, R. G. (1992) Cell 68, 673–682
32. Nichols, B. J., Kenworthy, A. K., Polishchuk, R. S., Lodge, R., Roberts, T.H.,
Hirschberg, K., Phair, R. D., and Lippincott-Schwartz, J. (2001) J. Cell Biol.
153, 529–541
33. Bradley, J. R., Johnson, D. R., and Pober, J. S. (1993) J. Immunol. 150,
5544–5555
34. Nandi, P. K., Van Jaarsveld, P. P., Lippoldt, R. E., and Edelhoch, H. (1981)
Biochemistry 20, 6706–6710
35. Sin, N., Kim, K. B., Elofsson, M., Meng, L., Auth, H., Kwok, B. H., and
Crews, C. M. (1999) Bioorg. Med. Chem. Lett. 9, 2283–2288
36. Schwarz, K., de Giuli, R., Schmidtke, G., Kostka, S., van den, B. M., Kim,
K. B., Crews, C. M., Kraft, R., and Groettrup, M. (2000) J. Immunol. 164,
6147–6157
37. Mellman, I., Fuchs, R., and Helenius, A. (1986) Annu. Rev. Biochem. 55,
663–700
38. Kalina, M., and Socher, R. (1991) J. Histochem. Cytochem. 39, 1337–1348
39. Ljunggren, H. G., Van Kaer, L., Sabatine, M. S., Auchincloss, H., Jr.,
Tonegawa, S., and Ploegh, H. L. (1995) Int. Immunol. 7, 975–984
40. Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G.,
Knetter, C. F., Lien, E., Nilsen, N. J., Espevik, T., and Golenbock, D. T.
(2004) Nat. Immunol. 5, 190–198
Internalization and Routing of TLR Ligand-Peptide Conjugates
21158 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 29•JULY 20, 2007
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
41. Jeannin, P., Magistrelli, G., Goetsch, L., Haeuw, J. F., Thieblemont, N.,
Bonnefoy, J. Y., and Delneste, Y. (2002) Vaccine 20, Suppl. 4, 23–27
42. Jeannin, P., Bottazzi, B., Sironi, M., Doni, A., Rusnati, M., Presta, M.,
Maina, V., Magistrelli, G., Haeuw, J. F., Hoeffel, G., Thieblemont, N., Cor-
vaia, N., Garlanda, C., Delneste, Y., and Mantovani, A. (2005) Immunity
22, 551–560
43. Triantafilou, M., Manukyan, M., Mackie, A., Morath, S., Hartung, T.,
Heine, H., and Triantafilou, K. (2004) J. Biol. Chem. 279, 40882–40889
44. Seglen, P. O. (1983)Methods Enzymol. 96, 737–764
45. Yewdell, J.W., Norbury, C. C., and Bennink, J. R. (1999)Adv. Immunol. 73,
1–77
46. Hart, P. D., and Young, M. R. (1991) J. Exp. Med. 174, 881–889
47. Shen, L., Sigal, L. J., Boes,M., andRock, K. L. (2004) Immunity21, 155–165
48. Tanaka, K., Ii, K., Ichihara, A., Waxman, L., and Goldberg, A. L. (1986)
J. Biol. Chem. 261, 15197–15203
49. Tanaka, K., Kumatori, A., Ii, K., and Ichihara, A. (1989) J. Cell. Physiol. 139,
34–41
50. Ackerman, A. L., Giodini, A., and Cresswell, P. (2006) Immunity. 25,
607–617
51. Blander, J. M., and Medzhitov, R. (2006) Nature 440, 808–812
Internalization and Routing of TLR Ligand-Peptide Conjugates
JULY 20, 2007•VOLUME 282•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 21159
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Ossendorp
Gijsbert A. van der Marel, Dmitri V. Filippov, Sjoerd H. van der Burg and Ferry
Thorbald van Hall, Jan W. Drijfhout, Cornelis J. M. Melief, Hermen S. Overkleeft, 
Selina Khan, Martijn S. Bijker, Jimmy J. Weterings, Hans J. Tanke, Gosse J. Adema,
Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells
Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different
doi: 10.1074/jbc.M701705200 originally published online April 26, 2007
2007, 282:21145-21159.J. Biol. Chem. 
  
 10.1074/jbc.M701705200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/282/29/21145.full.html#ref-list-1
This article cites 49 references, 20 of which can be accessed free at
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
